Balyasny Asset Management
AUPH icon

Balyasny Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Balyasny Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-217,781
Closed -$2.41M – 3071
2025
Q3 		$2.41M Buy
+217,781
New +$2.38M ﹤0.01% 1720
2025
Q2 		– Sell
-110,983
Closed -$892K – 2810
2025
Q1 		$892K Buy
110,983
+63,471
+134% +$514K ﹤0.01% 2044
2024
Q4 		$427K Buy
+47,512
New +$388K ﹤0.01% 2249
2024
Q2 		– Sell
-288,875
Closed -$1.45M – 2558
2024
Q1 		$1.45M Sell
288,875
-598,139
-67% -$4.06M ﹤0.01% 1655
2023
Q4 		$7.97M Buy
887,014
+624,186
+237% +$5.14M 0.02% 942
2023
Q3 		$2.04M Sell
262,828
-542,706
-67% -$5.31M ﹤0.01% 1370
2023
Q2 		$7.8M Sell
805,534
-506,813
-39% -$5.26M 0.02% 887
2023
Q1 		$14.4M Buy
1,312,347
+852,516
+185% +$7.51M 0.04% 633
2022
Q4 		$1.99M Sell
459,831
-393,956
-46% -$2.29M 0.01% 1433
2022
Q3 		$6.42M Buy
853,787
+354,536
+71% +$3.07M 0.02% 886
2022
Q2 		$5.02M Sell
499,251
-43,351
-8% -$485K 0.02% 932
2022
Q1 		$6.72M Buy
+542,602
New +$8.39M 0.02% 840
2018
Q1 		– Sell
-500,000
Closed -$2.27M – 1924
2017
Q4 		$2.27M Hold
500,000
– – 0.01% 1102
2017
Q3 		$3.13M Hold
500,000
– – 0.01% 856
2017
Q2 		$3.06M Buy
500,000
+200,000
+67% +$1.35M 0.01% 859
2017
Q1 		$2.2M Buy
+300,000
New +$1.39M 0.01% 891

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's AUPH Position: Q4 2025 in Review

Balyasny Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 217,781 shares — an estimated $2.41M sold.

Balyasny Asset Management first reported a position in AUPH in Q1 2017 and held it in 16 quarters. The position peaked at $14.4M in Q1 2023. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • Balyasny Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 217,781 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $2.41M.
  • Balyasny Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 16 quarters.
  • Balyasny Asset Management's Aurinia Pharmaceuticals position peaked at $14.4M in Q1 2023.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.